Perrigo launches generic Zaditor
This article was originally published in The Tan Sheet
Executive Summary
Perrigo ships its generic of Novartis Pharmaceuticals' Zaditor, a ketotifen fumarate ophthalmic solution, .025 percent, the Allegan, Mich.-based private labeler says in a March 15 release. Perrigo CEO Joseph Papa said the firm is "excited to launch into a new adjacent OTC category, ophthalmics." Zaditor is a solution used to temporarily prevent allergic conjunctivitis. Wolters Kluwer data estimates the annual sales of Zaditor in the last 12 months reached $15 million, Perrigo said. Competition in the eye-care market increased with the recent launch of Johnson & Johnson/McNeil's Zyrtec Allergy Eye Relief Drops and Schering-Plough's Claritin Eye, which also contain ketotifen fumarate as the active ingredient (1"The Tan Sheet" Jan. 11, 2010)
You may also be interested in...
Zyrtec and Claritin Eye Drops Use Different Tactics In Head To Head Fight
Thanks to a multi-media blitz, McNeil's Zyrtec Allergy Eye Relief Drops secured nearly twice the market share as a Claritin product from Schering-Plough with the same active drug that launched at the same time in summer 2009
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.